(NASDAQ: CDXS) Codexis's forecast annual revenue growth rate of 34.21% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 118.19%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.42%.
Codexis's revenue in 2026 is $52,932,000.On average, 8 Wall Street analysts forecast CDXS's revenue for 2026 to be $6,522,955,967, with the lowest CDXS revenue forecast at $4,762,262,769, and the highest CDXS revenue forecast at $7,844,311,366. On average, 6 Wall Street analysts forecast CDXS's revenue for 2027 to be $8,756,948,932, with the lowest CDXS revenue forecast at $8,019,540,669, and the highest CDXS revenue forecast at $9,437,091,536.
In 2028, CDXS is forecast to generate $11,701,523,818 in revenue, with the lowest revenue forecast at $9,506,641,311 and the highest revenue forecast at $14,781,585,278.